Evidence map›Paper›PMID 36371660›Full record

ArticleHeart (British Cardiac Society)2022

Echocardiographic features of left ventricular dysfunction and outcomes in chronic kidney disease.

Shuo-Ming Ou, Chieh-Ju Chao, Ming-Tsun Tsai, Kuo-Hua Lee, Wei-Cheng Tseng, Pin-Jie Bin, Yao-Ping Lin, Chien-Yi Hsu, Der-Cherng Tarng

Open access · hybridAbstract read
In one paragraph

Article in Heart (British Cardiac Society), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Observational
  3. Article
  4. Imaging of Congestion in Cardio-renal Syndrome.Current heart failure reports · 2025
    Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Shuo-Ming OuDivision of Nephrology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.
Chieh-Ju ChaoDepartment of Cardiovascular Diseases, Mayo Clinic Rochester, Rochester, Minnesota, USA.
Ming-Tsun TsaiDivision of Nephrology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.
Kuo-Hua LeeDivision of Nephrology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.ORCID 0000-0002-6314-8788
Wei-Cheng TsengDivision of Nephrology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.ORCID 0000-0002-6940-9651
Pin-Jie BinGraduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.
Yao-Ping LinDivision of Nephrology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.
Chien-Yi Hsu *Division of Cardiology and Cardiovascular Research Center, Department of Internal Medicine, Taipei Medical University Hospital, Taipei, Taiwan chienyihsu@tmu.edu.tw dctarng@vghtpe.gov.tw.ORCID 0000-0002-9493-7325
Der-Cherng Tarng *Division of Nephrology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan chienyihsu@tmu.edu.tw dctarng@vghtpe.gov.tw.ORCID 0000-0001-9017-2081
National Yang Ming Chiao Tung University · TWKaohsiung Medical University · TWMayo Clinic · USTaipei Medical University Hospital · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveHeart failure (HF) imposes a substantial burden and the prevalence of HF is high in patients with chronic kidney disease (CKD). HF results in multiple hospital admissions, but whether HF subtypes worsen long-term outcomes and renal function in patients with CKD remains inconclusive.

methodsThe study comprised 10 904 patients with CKD aged ≥20 years who underwent echocardiography between 1 January 2011 and 31 December 2018. The patients were stratified into four groups: non-HF, HF with reduced ejection fraction (HFrEF), HF with mildly reduced ejection fraction (HFmrEF) and HF with preserved ejection fraction (HFpEF). The primary end points were all-cause mortality, major adverse cardiovascular events (MACEs) and adverse renal outcomes.

resultsIn inverse probability of treatment weighting-adjusted method, the risk of all-cause mortality and MACEs relative to the non-HF group was greatest in the HFrEF group (HR 3.18 (95% CI 2.57 to 3.93) and HR 3.83 (95% CI 3.20 to 4.59)), followed by the HFmrEF (HR 2.75 (95% CI 2.22 to 3.42) and HR 3.08 (95% CI 2.57 to 3.69)) and HFpEF (HR 1.85 (95% CI 1.59 to 2.15) and HR 2.43 (95% CI 2.16 to 2.73) groups. In addition, the HFrEF group had the greatest risks of end-stage renal disease (HR 2.58 (95% CI 1.94 to 3.44)) compared with other groups.

conclusionsHF is associated with subsequent worse clinical outcomes, which may be more pronounced in patients with HFrEF, followed by those with HFmrEF and those with HFpEF relative to non-HF group.

Indexed as

Heart FailureRenal Insufficiency, ChronicVentricular Dysfunction, LeftEchocardiographyHumansPrognosisStroke VolumeVentricular Function, Leftechocardiographyepidemiologyheart failure, diastolicheart failure, systolic

Identifiers

PMID36371660
PMCPMC9811083
OpenAlexW4293495645

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.